DHTRF
DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.
DHTRF (DHTRF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.025x
Based on the latest financial reports, DHTRF (DHTRF) has a cash flow conversion efficiency ratio of -0.025x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.14 Million) by net assets ($437.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
DHTRF - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how DHTRF's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
DHTRF Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DHTRF ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
New Mountain Finance Corporation
NASDAQ:NMFC
|
0.018x |
|
DAIWA SEC GRP - Dusseldorf Stock Exchang
DU:DSE
|
N/A |
|
Trustpilot Group PLC
LSE:TRST
|
0.675x |
|
MALAGASY MINER
BE:MGM
|
N/A |
|
Decoy Therapeutics Inc.
NASDAQ:DCOY
|
-0.388x |
|
HELIX ENERGY SOLNS
MU:CTV
|
0.035x |
|
ASURE SOFTWARE (VTE1.SG)
STU:VTE1
|
0.007x |
|
TAKIX
NMFQS:TAKIX
|
N/A |
Annual Cash Flow Conversion Efficiency for DHTRF (2021–2024)
The table below shows the annual cash flow conversion efficiency of DHTRF from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | $527.53 Million | $155.41 Million | 0.295x | +115.87% |
| 2023-09-30 | $559.70 Million | $76.38 Million | 0.136x | -34.41% |
| 2022-09-30 | $372.34 Million | $77.47 Million | 0.208x | -14.17% |
| 2021-09-30 | $378.99 Million | $91.86 Million | 0.242x | -- |